TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01749748

Intervention type: PROCEDURE
Group type: OTHER
Intervention: proton magnetic resonance spectroscopy
Description: proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
Study: NCT01323452

Intervention type: DRUG
Intervention: Entecavir
Description: once daily
Study: NCT01157715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of KH902
Study: NCT02908178

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy (SLNB)
Description: Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
Study: NCT04017130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-0169
Description: MT-0169 intravenous infusion.
Study: NCT01775540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Ultra
Description: Artificial tear Eyedrop, 1 drop used QID for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution,1 drop used QID for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxidex
Description: Eyedrop-1 drop QID for 4 weeks
Study: NCT01938729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection and placement of hepatic artery infusion pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOXURIDINE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXAMETHASONE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMCITABINE
Study: NCT02320656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Longitudinal (3 stages of the disease)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate
Description: Longitudinal (3 stages of the disease)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Single biopsy (optional)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buccal swab
Description: Single sampling.
Study: NCT04490681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Fixed dose Ertugliflozin (5mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study: NCT02109276

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spheric Sensar(R) 3-piece IOL
Description: Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspheric Tecnis(R) 3-piece IOL
Description: Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
Study: NCT03848780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study: NCT01858727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: forced air warming group
Description: 30 minutes before the preoperative will use forced air warming

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: do not heating group
Study: NCT03525509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride
Description: Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
Study: NCT02349061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV
Description: Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Infusion
Description: Placebo intravenously at Week 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo subcutaneously at Weeks 8 and 16.
Study: NCT01138514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)
Description: Applied to the entire face twice daily for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
Description: Applied to the entire face twice daily for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00399087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral administration
Study: NCT00016354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benzoylphenylurea
Study: NCT03791879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamedatomidine analgesia
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamedatomidine analgesia
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamedatomidine analgesia
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamedatomidine analgesia
Description: Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.
Study: NCT03201120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Sun Behavior
Description: Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Tanning Behavior
Description: Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
Study: NCT01564017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot
Description: Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allergovac depot
Description: Sterile suspension for subcutaneous injection.~Same number of administration as the active groups
Study: NCT04487405

Intervention type: DEVICE
Intervention: OVAnex
Description: OVAnex is a multivarite index assay assessing ovarian cancer risk
Study: NCT04561219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500mg three times a day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day for 5 days
Study: NCT02873312

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: StimRouter
Description: The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter
Description: The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.
Study: NCT01483248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional therapy plus MenSC transplantation
Description: patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy plus placebo treatment
Description: 25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
Study: NCT02349061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC
Description: Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
Study: NCT00604019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine 5-20 mcg/kg/min to pre-determined max of 20
Study: NCT03314181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Infusion; Intravenous (IV), or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study: NCT02573935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: p.o. clarithromycin 500 mg twice daily for 63 days
Study: NCT03314181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study: NCT02573935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 63 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCD induction therapy
Description: Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
Study: NCT03314181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study: NCT02136199

Intervention type: OTHER
Group type: OTHER
Intervention: Active Implementation of ShareEBM Toolkit

Intervention type: OTHER
Group type: OTHER
Intervention: Passive Dissemination of Share EBM
Study: NCT04346264

Intervention type: DIAGNOSTIC_TEST
Intervention: NO intervention planned due to the observational study design only a diagnostic testing
Description: Only a diagnostic test (serum blood and antibody measurement) is planned
Study: NCT00604019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
Study: NCT03229044

Intervention type: GENETIC
Intervention: Tetranectin
Description: Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue

Intervention type: GENETIC
Intervention: Tetranectin
Description: Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
Study: NCT01670656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)
Description: Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)
Description: Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel containing contraceptive vaginal ring (ENG-CVR)
Description: Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel containing contraceptive vaginal ring (ENG-CVR)
Description: Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match vaginal ring, intravaginally for two 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
Study: NCT03229044

Intervention type: GENETIC
Intervention: Tetranectin
Description: Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue